Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cablivi CHMP Backing Helps Validate Sanofi's €3.9bn Ablynx Purchase

Executive Summary

Cablivi is first therapeutic to receive positive CHMP opinion for treating acquired thrombotic thrombocytopenic purpura, a rare blood disorder.

Advertisement

Related Content

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019
Sanofi Prioritizes Cancer And Rare Diseases In Pipeline Shake-Up
Mentioned In Despatches: Ablynx's Story From The Frontline Of The Biotech Boom
Q4 Pharma Earnings Preview: GSK, Lilly, Sanofi And AstraZeneca
Sanofi's Vaccines Performance Helps Offset Diabetes Decline
Keeping Track: J&J Esketamine, Sanofi Caplacizumab Lead Off September Submissions; US FDA Says No To Nucala
Novo Outbid As Sanofi Agrees €3.9bn Ablynx Acquisition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123339

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel